Thanks to significant technological advances, genome editing is becoming increasingly accessible. The healthcare applications of such innovations offer great potential for personalized medicine and the understanding of many diseases. However, genome-editing techniques also carry safety risks and raise ethical questions. While the potential benefits of genetic therapies on somatic cells could be significant, related scientific practices remain largely unsupervised and access to these therapies is limited. On the other hand, the hereditary modifications enabled by genome editing of embryos are widely decried as unethical. Leading institutions have established governance frameworks to define the parameters for the ethical use of this technology, while working with regulators to apply relevant norms and standards. In a complex international environment, how can we bring this issue to the fore at the political level, so as to define the limits to the use of this biotechnology, while at the same time allowing us to benefit from its potential advantages? Follow us on social media โข ๐ง๐๐ถ๐๐๐ฒ๐ฟ - โข ๐๐ถ๐ป๐ธ๐ฒ๐ฑ๐๐ป - โข ๐๐ฎ๐ฐ๐ฒ๐ฏ๐ผ๐ผ๐ธ - โข ๐๐ป๐๐๐ฎ๐ด๐ฟ๐ฎ๐บ - โข ๐ง๐ถ๐ธ๐ง๐ผ๐ธ - @parispeaceforum_
Hide player controls
Hide resume playing